Current Hematologic Malignancy Reports

, Volume 3, Issue 1, pp 5–9

Lenalidomide in myelodysplastic syndromes: Where do we go from here?

Article
  • 29 Downloads

Abstract

Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more recently, lenalidomide has changed the paradigm so that supportive treatment for patients who are not candidates for transplantation now includes drugs that may alter the natural history of the disease. The remarkable results observed with lenalidomide in patients with del(5q) has promoted intense research into the pathobiology of MDS and new approaches to treatment; it is hoped that this success will be extended to all subtypes of patients with MDS.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Goldberg SL, Mody-Patel N, Warnock N: Incidence of myelodysplastic syndromes in the United States Medicare population. Leuk Res 2007, 31(Suppl 1):S41.CrossRefGoogle Scholar
  2. 2.
    Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189–199.PubMedGoogle Scholar
  3. 3.
    Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292–2302.PubMedCrossRefGoogle Scholar
  4. 4.
    Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079–2088.PubMedGoogle Scholar
  5. 5.
    Malcovati L, Porta MG, Pascutto C, et al.: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594–7603.PubMedCrossRefGoogle Scholar
  6. 6.
    Haase D, Steidl C, Schanz J, et al.: Correlation of cytogenetic findings with morphology, clinical course and prognosis in 2124 patients with MDS [abstract]. Blood 2005, 106:787.CrossRefGoogle Scholar
  7. 7.
    Van den Berghe H, Cassiman JJ, David G, et al.: Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974, 251:437–438.PubMedCrossRefGoogle Scholar
  8. 8.
    Corey SJ, Minden MD, Barber DL, et al.: Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007, 7:118–129.PubMedCrossRefGoogle Scholar
  9. 9.
    Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429–2440.PubMedCrossRefGoogle Scholar
  10. 10.
    Kantarjian H, Issa JP, Rosenfeld CS, et al.: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794–1803.PubMedCrossRefGoogle Scholar
  11. 11.
    Pruneri G, Bertolini F, Soligo D, et al.: Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999, 81:1398–1401.PubMedCrossRefGoogle Scholar
  12. 12.
    Bellamy WT, Richter L, Sirjani D, et al.: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427–1434.PubMedCrossRefGoogle Scholar
  13. 13.
    Raza A, Meyer P, Dutt D, et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98:958–965.PubMedCrossRefGoogle Scholar
  14. 14.
    Crane E, List A: Immunomodulatory drugs. Cancer Invest 2005, 23:625–634.PubMedCrossRefGoogle Scholar
  15. 15.
    List A, Kurtin S, Roe DJ, et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549–557.PubMedCrossRefGoogle Scholar
  16. 16.
    List A, Dewald G, Bennett J, et al.: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456–1465.PubMedCrossRefGoogle Scholar
  17. 17.
    List AF, Wride K, Dewald G, et al.: Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletions. Leuk Res 2007, 31(Suppl 1):S38.CrossRefGoogle Scholar
  18. 18.
    Sekeres MA, Maciejewski JP, Giagounidis A, et al.: Cytopenias correlate with response to lenalidomide in del 5q MDS patients. Leuk Res 2007, 31(Suppl 1):S37.CrossRefGoogle Scholar
  19. 19.
    Raza A, Reeves JE, Feldman EJ, et al.: Phase II study of lenalidomide in transfusion-dependent, lower-risk myelodysplastic syndromes with karyotypes other than the deletion 5q cytogenetic abnormality. Blood 2007, In press.Google Scholar
  20. 20.
    Mohamedali A, Gaken J, Twine NA, et al.: Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007, 110:3365–3373.PubMedCrossRefGoogle Scholar
  21. 21.
    Langemeijer S, Kuiper R, vd Reijden BA, et al.: Identification of novel genetic lesions in MDS using high density SNP-arrays. Leuk Res 2007, 31(Suppl 1):S33.CrossRefGoogle Scholar
  22. 22.
    Sutton L, Chastang C, Ribaud P, et al.: Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 1996, 88:358–365.PubMedGoogle Scholar
  23. 23.
    Arnold R, de Witte T, van Biezen A, et al.: Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 1998, 21:1213–1216.PubMedCrossRefGoogle Scholar
  24. 24.
    Parker JE, Shafi T, Pagliuca A, et al.: Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002, 119:144–154.PubMedCrossRefGoogle Scholar
  25. 25.
    Cutler CS, Lee SJ, Greenberg P, et al.: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579–585.PubMedCrossRefGoogle Scholar
  26. 26.
    Nevill TJ, Shepherd JD, Reece DE, et al.: Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 1992, 10:445–450.PubMedGoogle Scholar
  27. 27.
    Anderson JE, Appelbaum FR, Storb R: An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymphoma 1995, 17:95–99.PubMedCrossRefGoogle Scholar
  28. 28.
    Alyea EP, Kim HT, Ho V, et al.: Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006, 12:1047–1055.PubMedCrossRefGoogle Scholar
  29. 29.
    Sorror ML, Sandmaier BM, Storer BE, et al.: Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007, 25:4246–4254.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Harvard Medical School, Department of Medical OncologyDana-Farber Cancer InstituteBostonUSA

Personalised recommendations